Gsk Plc · LSE:GSK
Gsk — Investor Day (November 2023)
34 slides from Gsk's investor day presentation, Nov 30, 2023
Slide 1: Meet GSK management: Getting ahead of respiratory diseases
30 November 2023 Meet GSK management Getting ahead of respiratory diseases Interactive event for investors and analysts. This webinar is being recorded. @ gsk.com
Slide 2: Cautionary statement regarding forward-looking statements
> Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly
Slide 3: Today's speakers
Today’s speakers Dr Tony Wood Chief Scientific Officer Luke Miels Chief Commercial Officer GSK
Slide 4: GSK prevents and treats disease in four core therapy areas
> GSK prevents and treats disease in four core therapy areas Vaccines Infectious Dise Specialty General Medicines ology Seel tions for blood and women's ers and break- Regie rei < > HIV Novel treatment and prevention options to significantly improve the patient experience Respiratory/ Enabled by adv
Slide 5: Today's focus
Today’s focus ° Our expertise in Respiratory * Our treatment approach from symptom control to disease modification ¢ The importance and updated potential of IL-5, Nucala and depemokimab ° Market potential of Refractory Chronic Cough (RCC) and camlipixant’s differentiation ° Key respiratory data read
Slide 6: Leader in respiratory: innovator of small molecules, biologics and vaccines
Innovator of small molecules in easy-to-use devices * 1969: Ventolin: Ist selective SABA for asthma * 1998: Seretide/Advair. Ist ICS/LABA’ combination for asthma * 2013: AnororJst 4 LABA/LAMA’ for COPD 2017: Trelegy. ist single once-daily ICS/LABA/LAMA combination inhaler launched for COPD Best-in-c
Slide 7: Respiratory portfolio sales by product
Trelegy Nucala Ellipta portfolio Established respiratory COVID-19 Fluarix Other
Slide 8: To treat respiratory disease remains an area of high unmet need
> To treat respiratory disease remains an area of high unmet need A significant and growing burden to patients and society Asthma Chronic obstructive pulmonary disease ~315 million ~212 million individuals suffering from asthma worldwide individuals suffering from COPD worldwide 50-70% have eosinoph
Slide 9: Advancing treatment goals to clinical remission
> Advancing treatment goals to clinical remission Ambition to prevent Example: clinical remission in asthma and treat respiratory diseases by reducing signs and symptoms, addressing treatment resistance and vid ve slowing disease Present . Past Exacerbation p fog ression Bronchodilation reduction an
Slide 10: 10
10
Slide 11: Understanding the biological effects of IL-5
> Understanding the biological effects of IL-5 IL-5 plays a broad role beyond eosinophilic inflammation GSK 1
Slide 12: Eosinophils and IL-5 play a central role in controlling inflammation
> Eosinophils and IL-5 play a central role in controlling inflammation and its healthy resolution Eosinophils are a key driver of T2 inflammation; IL-5 is a key cytokine for type 2 processes Parasites Allergens — ee ©... & epithelial cell Epithelial cell bacteria oe © Mast cell Basophil © Eosinophil
Slide 13: Nucala sustained clinical remission in real-world evidence studies
> Nucala sustained clinical remission in real-world evidence studies Comprehensive clinical programme to generate evidence Forthcoming prospective studies examining clinical remission REALITI-A 2024 2025 2026 37% a lobal 2 SA-EP. Demonstrated that 37% REDES®-? of patients achieved four- Retrospectiv
Slide 14: Leading the science in COPD with an eosinophilic phenotype
> Leading the science in COPD with an eosinophilic phenotype MATINEE redesign increases chances of success for depemokimab COPD trials Nucala's METREX/METREO phase III trials MATINEE phase III patient population helped inform future development * Provided first demonstration of efficacy ° Stricter e
Slide 15: Depemokimab
Depemokimab Potential best-in-class next-generation IL-5 treatment for eosinophilic-led disease GSK als)
Slide 16: Lifecycle innovation in two versus seven years
lifecycle innovation in two versus seven years • • Placebo Depemokimab 10mg Depemokimab 100mg Depemokimab 2mg Depemokimab 30mg Depemokimab 300mg hronic rhinosinusitis with nasal polyps eosinophilic granulomatosis with polyangiitis 4. ypereosinophilic syndrome
Slide 17: High economic burden and a clear unmet medical need
> High economic burden and a clear unmet medical need Increased biologic use in respiratory will drive further market expansion Asthma COPD! 78,000 Ses@REAN 12,000 8% CAGR 16,000 10,000 14,000 S 12000 5 8,000 € € 3 10,000 es 8 8 6000 S 8,000 ry 3 3 % 6.000 = 4,000 = 2 4,000 2,000 2,000 0 0 2022 2031
Slide 18: Depemokimab: improved real-world efficacy with improved dosing
> Depemokimab: improved real-world efficacy with improved dosing Providing benefits for patients, payers and physicians Low levels of bio-penetration today! Expected benefits of depemokimab will drive biologics growth GSK Efficacy * Improved real-world efficacy outcomes * — First clinical studies to
Slide 19: Focused development to drive breadth of indications in two years
> Focused development to drive breadth of indications in two years Indication Nucala depemokimab benralizumab tezepelumab dupilumab Severe eosinophilic VY Phase Ill VY VY VY asthma CRSwNP! Vv Phase III 2025 2025 Vv EGPA VY Phase lll 2024 HES VY Phase Ill 2025 corp Phase Il Investment decision 2026 2
Slide 20: Depemokimab: high HCP willingness to prescribe, strong patient preference
> Depemokimab: high HCP willingness to prescribe, strong patient preference Physician Belief 73% physicians believe a 6-month biologic for asthma would be highly ‘beneficial™ 57% of HCPs would consider prescribing depemokimab to bio naive patients? Physician * none 4 F 66% of HCPs would consider swi
Slide 21: Depemokimab share will come from all biologics
> Depemokimab share will come from all biologics! Source of business HCPs believe that depemokimab would expand bio-penetration Eligible patients 20% who don't get a biologic today would be prescribed one if depemokimab were available? New biologic patients ml Nucala —mIL-5 class competitor G = —e |
Slide 22: Depemokimab: increased sales potential from £1-2 billion
> Depemokimab: increased sales potential from £1-2 billion Upgrading sales expectations depemokimab MB Nucala > £3 b Nn I depemetimab in peak year sales! * Accelerated lifecycle innovation includes potential launches for four indications between 2026 and 2027 * Twice-yearly dosing leads to increased
Slide 23: Camlipixant
Camlipixant Potential best-in-disease P2X3 antagonist in phase III development for treatment of refractory chronic cough GSK 23
Slide 24: Refractory chronic cough patient journey
GSK Refractory chronic cough patients often experience an emotionally taxing and lengthy journey as they seek to resolve their cough 24
Slide 25: Refractory chronic cough is a distinct neuropathic disorder
> Refractory chronic cough is a distinct neuropathic disorder Highly prevalent causing misery, pain, exhaustion, isolation Patient population! Significant patient burden?34 ~28 million diagnosed with symptoms >8 weeks > 5 O O coughs per day 7 10 9 Patient population! 50% ) Urinary incontinence ~10 m
Slide 26: Patients have few effective treatments; no licensed targeted therapies
> Patients have few effective treatments; no licensed targeted therapies* Cycle through multiple treatments and physicians without resolution ( > Refractory Chronic Cough (RCC) is a cough that lasts for >8 weeks despite optimal treatment of any underlying conditions! 2:$ 6 0 o% © of patients have tr
Slide 27: Refractory chronic cough: high burden, low treatment satisfaction
> Refractory chronic cough: high burden, low treatment satisfaction HCP’s have a high willingness to prescribe innovative treatments No standard of care, options today are poor! Specialists say RCC N% is extremely burdensome r Low HCP 3% satisfaction rate for current RCC treatments G Ss K 1 US RCC M
Slide 28: Camlipixant: potential best-in-disease medicine for RCC
> Camlipixant: potential best-in-disease medicine for RCC High selectivity for P2X3 drives efficacy with fewer off-target effects P2X3 selectivity provides potential SOOTHE phase IIb trial demonstrated SOOTHE phase IIb trial demonstrated efficacy & tolerability benefits 34% placebo-adjusted reductio
Slide 29: Camlipixant: phase III CALM programme, data expected in H2 2025
> Camlipixant: phase III CALM programme, data expected in H2 2025 Optimised study design ensures placebo effect and baseline characteristics Study population and primary endpoint * Refractory/unexplained chronic cough; Cough 21 year » CALM-1 and CALM-2: 825 participants per study * Endpoints:- 24H c
Slide 30: Camlipixant: strong physician preference versus competition
> Camlipixant: strong physician preference versus competition >£2.5bn PYS driven by leading class share in a large market with high unmet need Taste disturbance is a significant issue for competitor both in clinical studies and in real world Strong HCP preference for camlipixant profile versus compe
Slide 31: Respiratory medicines growth drivers
Nucala (COPD) B£.Q)5-lbn in peak sales! depemokimab >E3bn in peak year sales! camlipixant >£2.5bn in peak year sales! ‘cae ee Respiratory medicines growth drivers Despite triple therapy utilisation 40% of total COPD patients still exacerbate 37% of COPD patients have an eosinophilic phenotype 400k e
Slide 32: Forthcoming catalysts
§ ™ ’ Pr & Forthcoming catalysts al H1 2024 H2 2024 2025 2026+ MATINEE Phase III data readout > Nucala (COPD) Regulatory decisions Japan (CRSwNP) China (severe asthma) SWIFT 1 and SWIFT 2 ANCHOR 1 and NIMBLE DESTINY i Phase III data readout ANCHOR 2 Phase III data readout Phase II] data readout depe
Slide 33: Q&A
Slide 34: Use of GSK conference call, webcast and presentation slides
Use of GSK conference call, webcast and presentation slides The GSK ple webcast, conference call and presentation slides (together the ‘GSK materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sel